Table 3 Crude 5-year overall survival and hazard ratios for death for the total study population (n = 186)^a

Gender

Male

77

1.0 (reference)

Female

84

2.5 (1.2–5.2)

Age

1.1 (1.1–1.2)

≤65

98^b

>66–75

87

&≥76

61

Comorbidity

0

96^b

1.0 (reference)

1

74

3.4 (1.0–10.9)

≥2

69

4.9 (1.6–15.6)

Surgery

Elective

82

1.0 (reference)

Acute

1.5 (0.2–14.4)

Subsite

Left-sided colon

78

1.0 (0.5–2.2)

Right-sided colon

82

1.0 (reference)

Differentiation grade

Well/moderate

1.0 (reference)

Poor/undifferentiated

71

3.9 (1.6–9.3)

Lymph nodes evaluated

<10

80

1.4 (0.6–3.0)

≥10

81

1.0 (reference)

Tumor obstruction

No

82

1.0 (reference)

Yes

&#955;

2.1 (0.2–18.4)

Tumor perforation

No

82

1.0 (reference)

Yes

&#955;

3.4 (0.8–14.4)

Lymphangioinvasion

No

81^c

1.0 (reference)

Yes

&#955;

4.8 (1.2–18.7)

Microsatellite status

MSS

82

1.0 (reference)

MSI

74

1.8 (0.6–4.9)

KRAS

Wild type

82

1.0 (reference)

Mutant

77

1.7 (0.8–3.5)

BRAF

Wild type

81

1.0 (reference)

Mutant

76

0.7 (0.2–2.0)

PIK3CA

Wild type

80

1.0 (reference)

Mutant

&#955;

0.5 (0.1–1.8)